Ideas

Molecular therapy for body weight control, energy homeostasis and TIIDM: Cilostazol, a drug used in the treatment of peripheral vascular disease,  increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 5/January/2018, 11.27 pm
Molecular therapy for body weight control, energy homeostasis and TIIDM: Cilostazol, a drug used in the treatment of peripheral vascular disease,  increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 5/January/2018, 11.27 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour and metabolism by synthetic…

read more

Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  t-AUCB, Epicatechin and Marine (t-AUCBEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 6/January/2018, 11.18 pm
Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  t-AUCB, Epicatechin and Marine (t-AUCBEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 6/January/2018, 11.18 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for Cardiovascular Research (DZHK) partner…

read more

Anti-infective Therapy: Nifedipine, an antihypertensive drug, inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, & Interferon-stimulated gene 15, 6/January/2018,  11.05 pm
Anti-infective Therapy: Nifedipine, an antihypertensive drug, inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytial,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, & Interferon-stimulated gene 15, 6/January/2018,  11.05 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard Medical School, Charlestown, MA 02129, USA shows that “The IFITM proteins…

read more

Molecular therapy for body weight control, energy homeostasis and TIIDM: Hydralazine,  an anti-hypertensive drug, inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 6/January/2017, 10.53 am
Molecular therapy for body weight control, energy homeostasis and TIIDM: Hydralazine,  an anti-hypertensive drug, inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 6/January/2017, 10.53 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator of adipose insulin resistance.”…

read more

Natural product-based exercise mementics therapy for Metabolic disease: A pharmaceutical mixture encompassing Magnolol and Honokiol, isolated from Magnolia Officinalis/Grandiflora, increases PPARδ  and Foxo1 levels, inhibits glucose catabolism, preserves glucose levels, stimulates FA catabolism, delays the onset of hypoglycemia and boosts endurance exercise via down regulation of its target gene, 6/January/2018, 10.31 pm
Natural product-based exercise mementics therapy for Metabolic disease: A pharmaceutical mixture encompassing Magnolol and Honokiol, isolated from Magnolia Officinalis/Grandiflora, increases PPARδ  and Foxo1 levels, inhibits glucose catabolism, preserves glucose levels, stimulates FA catabolism, delays the onset of hypoglycemia and boosts endurance exercise via down regulation of its target gene, 6/January/2018, 10.31 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Department of Molecular Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA shows that “CRY1/2 Selectively Repress…

read more

Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  TPPU, Epicatechin and Matrine (TPPUEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 5/January/2018, 11.48 am
Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  TPPU, Epicatechin and Matrine (TPPUEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 5/January/2018, 11.48 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for Cardiovascular Research (DZHK) partner…

read more
Start Typing